109 related articles for article (PubMed ID: 15264681)
1. [Usefulness of serum markers in renal cell carcinoma].
Rubio Briones J; Iborra Juan I; Aznar E; Climent MA; López-Guerrero JA; Maíquez J; Monrós Lliso JL; Casanova Ramón-Borja J; Dumont Martínez R; Ricós Torrent JV; Solsona Narbón E
Actas Urol Esp; 2004 May; 28(5):381-6. PubMed ID: 15264681
[TBL] [Abstract][Full Text] [Related]
2. Relationship between serum ferritin levels and tumour status in patients with renal cell carcinoma.
Miyata Y; Koga S; Nishikido M; Hayashi T; Kanetake H
BJU Int; 2001 Dec; 88(9):974-7. PubMed ID: 11851623
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of five glycoprotein tumour markers (CEA, CA-50, CA-19-9, CA-125, CA-15-3) for the prognosis of renal-cell carcinoma.
Grankvist K; Ljungberg B; Rasmuson T
Int J Cancer; 1997 Apr; 74(2):233-6. PubMed ID: 9133462
[TBL] [Abstract][Full Text] [Related]
4. Tumour-associated trypsin inhibitor and renal cell carcinoma.
Meria P; Toubert ME; Cussenot O; Bassi S; Janssen T; Desgrandchamps F; Cortesse A; Schlageter MH; Teillac P; Le Duc A
Eur Urol; 1995; 27(3):223-6. PubMed ID: 7601186
[TBL] [Abstract][Full Text] [Related]
5. Serum ferritin as a clinical marker for renal cell carcinoma: influence of tumor volume.
Partin AW; Criley SR; Steiner MS; Hsieh K; Simons JW; Lumadue J; Carter HB; Marshall FF
Urology; 1995 Feb; 45(2):211-7. PubMed ID: 7855968
[TBL] [Abstract][Full Text] [Related]
6. Serum ferritin: a tumor marker for renal cell carcinoma.
Essen A; Ozen H; Ayhan A; Ergen A; Tasar C; Remzi F
J Urol; 1991 Jun; 145(6):1134-7. PubMed ID: 2033679
[TBL] [Abstract][Full Text] [Related]
7. Serum ferritin as a clinical marker for renal cell carcinoma: influence of tumor size and volume.
Kirkali Z; Güzelsoy M; Mungan MU; Kirkali G; Yörükoglu K
Urol Int; 1999; 62(1):21-5. PubMed ID: 10436426
[TBL] [Abstract][Full Text] [Related]
8. Serum Hepcidin and GDF-15 levels as prognostic markers in urothelial carcinoma of the upper urinary tract and renal cell carcinoma.
Traeger L; Ellermann I; Wiethoff H; Ihbe J; Gallitz I; Eveslage M; Moritz R; Herrmann E; Schrader AJ; Steinbicker AU
BMC Cancer; 2019 Jan; 19(1):74. PubMed ID: 30646851
[TBL] [Abstract][Full Text] [Related]
9. Serum and urine biomarkers for human renal cell carcinoma.
Pastore AL; Palleschi G; Silvestri L; Moschese D; Ricci S; Petrozza V; Carbone A; Di Carlo A
Dis Markers; 2015; 2015():251403. PubMed ID: 25922552
[TBL] [Abstract][Full Text] [Related]
10. [Serum ferritin determination: is it useful in the early diagnosis of renal carcinoma?].
D'Addessi A; Racioppi M; Zappacosta B; Fanasca A; De Michele T; Alcini E
Arch Ital Urol Androl; 1997 Dec; 69(5):283-6. PubMed ID: 9477611
[TBL] [Abstract][Full Text] [Related]
11. Serum levels of soluble interleukin-2 receptor in renal cell carcinoma.
Matsumoto T; Furukawa A; Sumiyoshi Y; Akiyama KY; Kanayama HO; Kagawa S
Urology; 1998 Jan; 51(1):145-9. PubMed ID: 9457310
[TBL] [Abstract][Full Text] [Related]
12. The usefulness of serum levels of CEA, CA 50, and ferritin in the management of renal cell cancer.
Kokociñska D; Rajchel K; Nalewajka E; Zagalski K
J Environ Pathol Toxicol Oncol; 1996; 15(2-4):279-81. PubMed ID: 9216822
[TBL] [Abstract][Full Text] [Related]
13. Soluble interleukin-2 receptor levels in patients with malignant melanoma and renal cell cancer.
Ostenstad B
Acta Oncol; 1992; 31(4):413-5. PubMed ID: 1632975
[TBL] [Abstract][Full Text] [Related]
14. Predictive value of serum immunosuppressive acidic protein for staging renal cell carcinoma: comparison with other tumour markers.
Masuda H; Kurita Y; Suzuki K; Fujita K; Aso Y
Br J Urol; 1997 Jul; 80(1):25-9. PubMed ID: 9240175
[TBL] [Abstract][Full Text] [Related]
15. Tumour necrosis factor-alpha, interleukin-1 beta and interleukin-6 in patients with renal cell carcinoma.
Dosquet C; Schaetz A; Faucher C; Lepage E; Wautier JL; Richard F; Cabane J
Eur J Cancer; 1994; 30A(2):162-7. PubMed ID: 8155390
[TBL] [Abstract][Full Text] [Related]
16. Serum tissue factor as a biomarker for renal clear cell carcinoma.
Silva DD; Noronha JAP; Pinheiro da Costa BE; Zandona PCE; Carvalhal GF
Int Braz J Urol; 2018; 44(1):38-44. PubMed ID: 28727370
[TBL] [Abstract][Full Text] [Related]
17. Tissue polypeptide-specific antigen in renal cell carcinoma.
Höbarth K; Hallas A; Kramer G; Aulitzky W; Gomahr A; Steiner G; Marberger M
Eur Urol; 1996; 30(1):89-95. PubMed ID: 8854074
[TBL] [Abstract][Full Text] [Related]
18. Pretreatment serum markers and lymphocyte response to interleukin-2 therapy.
Fumagalli L; Lissoni P; Di Felice G; Meregalli S; Valsuani G; Mengo S; Rovelli F
Br J Cancer; 1999 May; 80(3-4):407-11. PubMed ID: 10408846
[TBL] [Abstract][Full Text] [Related]
19. Serum iron as a tumor marker in renal cell carcinoma.
Yu CC; Chen KK; Chen MT; Huang JK; Lin AT; Lee YH; Chang LS
Eur Urol; 1991; 19(1):54-8. PubMed ID: 2007419
[TBL] [Abstract][Full Text] [Related]
20. Pretreatment with interleukin-2 modulates peri-operative immuno-dysfunction in patients with renal cell carcinoma.
Böhm M; Ittenson A; Schierbaum KF; Röhl FW; Ansorge S; Allhoff EP
Eur Urol; 2002 Apr; 41(4):458-67; discussion 467-8. PubMed ID: 12074819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
